Upcoming event

Tags

Show all

Performance and inter-observer variability of prostate MRI (PI-RADS version 2) outside high-volume centres

Scandinavian Journal of Urology, October 2019

Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial

The Lancet Oncology, October 2019

Predicting prostate cancer death with different pretreatment risk stratification tools: A head-to-head comparison in a nationwide cohort study

European Urology, October 2019

Benefit of prostate radiotherapy for patients with lymph node only or < 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site and number in the STAMPEDE “M1/RT comparison”

September 2019

Timing of radiotherapy (RT) after radical prostatectomy (RP): first results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047]

September 2019

Docetaxel for hormone-naïve prostate cancer: results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial NCT00268476 and sub group analysis by metastatic burden

September 2019

Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer

The New England Journal of Medicine, September 2019

Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers

European Urology, September 2019

Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer

European Urology, August 2019

Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: A prospective cohort study

European Urology, September 2019

Prospective validation of gallium-68 PSMA-PET/CT in primary staging of prostate cancer patients

The Journal of Urology, September 2019

A 25-year period analysis of other-cause mortality in localized prostate cancer

Clinical Genitourinary Cancer, July 2019

Next